Fate Therapeutics (FATE) Cash & Equivalents (2012 - 2026)

Fate Therapeutics has reported Cash & Equivalents for 15 years, with the latest figure at $174.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 289.14% year-over-year to $174.8 million; the trailing twelve-month figure through Mar 2026 stood at $174.8 million (up 289.14% YoY), and the FY2025 full-year result was $46.6 million, up 29.32% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $174.8 million, up from $46.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $174.8 million in Q1 2026, with the low at $33.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $59.3 million across 5 years, with a median of $44.9 million in 2025.
• Annual changes were most pronounced in 2025 — Cash & Equivalents slumped 62.97% — and 2026, when it soared 289.14%.
• Fate Therapeutics' Cash & Equivalents stood at $61.3 million in 2022, then slumped by 31.73% to $41.9 million in 2023, then decreased by 13.89% to $36.1 million in 2024, then gained by 29.32% to $46.6 million in 2025, then surged by 274.88% to $174.8 million in 2026.
• The last three Cash & Equivalents figures came in at $174.8 million (Q1 2026), $46.6 million (Q4 2025), and $40.6 million (Q3 2025), per Business Quant data.